Tarsus Pharmaceuticals, Inc. TARS
70.84 USD +2.24 (+3.27%)
At closeNov 9, 2026, 5:41 PM EST
70.84 0.00 0.00%
After hours · Nov 9, 5:41 PM ET
67.45 Day range 71.20
53.89 52-week range 91.53
- YTD
- -13.48%
- 1 year
- +3.79%
News
benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.
benzinga.com HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $106 HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $106.
marketbeat.com Tarsus Pharmaceuticals Q3 Earnings Call Highlights Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye…
seekingalpha.com Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
zacks.com Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.
benzinga.com UPDATE: Tarsus Pharmaceuticals Q3 Adj. EPS $(0.78) Beats $(2.73) Estimate, Sales $194.569M Beat $186.598M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(2.73) by 71.43 percent. This is a 160 percent decrease over losses…
benzinga.com Tarsus Pharmaceuticals Q3 2026 Earnings Call Transcript Tarsus Pharmaceuticals (NASDAQ:TARS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in…
zacks.com How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78% The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is…
benzinga.com Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.
benzinga.com Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.
benzinga.com Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105 Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.
benzinga.com Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and…
benzinga.com Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100 Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.- benzinga.com Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses…
- benzinga.com Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not Disclosed Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of…
- benzinga.com Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98 Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.
- benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89 Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $90 to $89.
benzinga.com Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the deal a disciplined pipeline expansion.- benzinga.com HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
- benzinga.com Tarsus Acquires iRenix Medical And Late-Stage Asset IRX-101 For ~$75M IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of carePositive Phase 2b/3 data and an FDA-aligned Phase 3 program provide…
benzinga.com Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal…- benzinga.com Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
- benzinga.com Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs – A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals,…
- benzinga.com Tarsus Pharmaceuticals Announces $15M Milestone Payment Achieved After Regulatory Approval Of TP-03 By China's National Medical Products Administration Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution)…
- benzinga.com Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105 Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $95 to $105.
- benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.
benzinga.com Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday - benzinga.com Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over…
benzinga.com Insights into Tarsus Pharmaceuticals Q4 Earnings - benzinga.com Earnings Scheduled For February 23, 2026
benzinga.com Earnings Preview: Tarsus Pharmaceuticals - benzinga.com Barclays Initiates Coverage On Tarsus Pharmaceuticals with Overweight Rating, Announces Price Target of $100 Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight rating and announces Price Target of $100.
- benzinga.com Mizuho Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $100 Mizuho analyst Graig Suvannavejh initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform rating and announces Price Target of $100.
- benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $87 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $84 to $87.
benzinga.com Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.38) by 21.88 percent. This is a 50.82 percent increase over losses…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $88 HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $72 to $88.
benzinga.com Top 2 Health Care Stocks That May Fall Off A Cliff In August - benzinga.com Tarsus Pharmaceuticals Q2 EPS $(0.48) Misses $(0.39) Estimate, Sales $102.660M Beat $95.682M Estimate Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 45.45 percent increase over…
- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
- benzinga.com HC Wainwright & Co. Assumes Tarsus Pharmaceuticals at Buy, Announces Price Target of $72 HC Wainwright & Co. analyst Matthew Caufield assumes Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and announces Price Target of $72.
- benzinga.com 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know
benzinga.com Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.- benzinga.com Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $51 Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target from $46 to $51.
- benzinga.com Elanco Monetizes XDEMVY Royalties in $295M Deal to Lower Debt and Reduce Interest Costs Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for…
- benzinga.com Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $84 Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $78 to $84.